GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Korean Cancer Association  (8)
  • 1
    Online Resource
    Online Resource
    Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
    Korean Cancer Association ; 2023
    In:  Cancer Research and Treatment
    Details
    In: Cancer Research and Treatment, Korean Cancer Association
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2022.1543
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2023
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment
    Korean Cancer Association ; 2024
    In:  Cancer Research and Treatment Vol. 56, No. 2 ( 2024-04-15), p. 624-633
    Details
    In: Cancer Research and Treatment, Korean Cancer Association, Vol. 56, No. 2 ( 2024-04-15), p. 624-633
    Abstract: Purpose Small cell carcinoma of the genitourinary tract (GU SCC) is a rare disease with a poor prognosis. There are only limited treatment options due to insufficient understanding of the disease. In this study, we analyzed the clinical outcomes of patients with GU SCC and their association with the tumor immune phenotype.Materials and Methods Patients diagnosed with GU SCC were included. Survival outcomes according to the primary location (prostate and non-prostate) and stages (limited disease [LD] and extensive disease [ED] ) were analyzed. We performed multiplex immunohistochemistry (IHC) in non-prostate SCC patients and analyzed the immune cell population.Results A total of 77 patients were included in this study. Their median age was 71 years, 67 patients (87.0%) were male, and 48 patients (62.3%) had non-prostate SCC. All patients with ED (n=31, 40.3%) received etoposide plus platinum (EP) as initial treatment and median overall survival (OS) was 9.7 months (95% confidence interval [CI], 7.1 to 18.6). Patients with LD (n=46, 59.7%) received EP followed by radiotherapy or surgery, and 24-months OS rate was 63.6% (95% CI, 49.9 to 81.0). The multiplex IHC analysis of 21 patients with non-prostate SCC showed that patients with a higher density of programmed death-ligand 1–expressing CD68+CD206+ M2-like macrophages had significantly worse OS outcomes with an adjusted hazards ratio of 4.17 (95% CI, 1.25 to 14.29; adjusted p=0.02).Conclusion Patients with GU SCC had a poor prognosis, even those with localized disease. The tumor immune phenotypes were significantly associated with survival. This finding provides new insights for treating GU SCC.
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2023.1076
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2024
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer
    Korean Cancer Association ; 2021
    In:  Cancer Research and Treatment Vol. 53, No. 1 ( 2021-01-15), p. 162-171
    Details
    In: Cancer Research and Treatment, Korean Cancer Association, Vol. 53, No. 1 ( 2021-01-15), p. 162-171
    Abstract: PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.Materials and MethodsA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.ResultsThe density of CD8 〈 sup 〉 + 〈 /sup 〉 T cells, FoxP3 〈 sup 〉 - 〈 /sup 〉 CD4 〈 sup 〉 + 〈 /sup 〉 helper T cells, and FoxP3 〈 sup 〉 + 〈 /sup 〉 CD4 〈 sup 〉 + 〈 /sup 〉 regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8 〈 sup 〉 + 〈 /sup 〉 T cell and FoxP3 〈 sup 〉 - 〈 /sup 〉 CD4 〈 sup 〉 + 〈 /sup 〉 helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3 〈 sup 〉 - 〈 /sup 〉 CD4 〈 sup 〉 + 〈 /sup 〉 helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3 〈 sup 〉 - 〈 /sup 〉 CD4 〈 sup 〉 + 〈 /sup 〉 helper T cells in the tumor margin was independently associated with favorable PFS and OS. ConclusionThe tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3 〈 sup 〉 - 〈 /sup 〉 CD4 〈 sup 〉 + 〈 /sup 〉 helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2020.704
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2021
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels
    Korean Cancer Association ; 2021
    In:  Cancer Research and Treatment Vol. 53, No. 3 ( 2021-07-15), p. 847-856
    Details
    In: Cancer Research and Treatment, Korean Cancer Association, Vol. 53, No. 3 ( 2021-07-15), p. 847-856
    Abstract: Purpose We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.Materials and Methods A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum β2-microglobulin levels. A risk-stratifying classification system incorporating serum β2-microglobulin levels was proposed and validated in an independent validation cohort (n=60).Results The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum β2-microglobulin levels ( 〉 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p 〈 0.01 for both). Serum β2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum β2-microglobulin level ( 〉 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum β2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes.Conclusion Serum β2-microglobulin level is an independent prognostic factor for BL patients. The proposed β2-microglobulin–based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2020.1060
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2021
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-Assessment for Initially HER2 Negative Advanced Gastric Cancer Patients After Progression on First-Line Treatment
    Korean Cancer Association ; 2023
    In:  Cancer Research and Treatment
    Details
    In: Cancer Research and Treatment, Korean Cancer Association
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2023.490
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2023
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
    Korean Cancer Association ; 2022
    In:  Cancer Research and Treatment Vol. 54, No. 4 ( 2022-10-15), p. 1167-1174
    Details
    In: Cancer Research and Treatment, Korean Cancer Association, Vol. 54, No. 4 ( 2022-10-15), p. 1167-1174
    Abstract: Purpose Three years of adjuvant imatinib is the standard treatment for resected gastrointestinal stromal tumors (GISTs) with rupture, but the recurrence rate is prominently high. We aimed to investigate the efficacy and safety of 5-year adjuvant imatinib compared with 3-year treatment in patients with a ruptured GIST following surgical resection.Materials and Methods A total of 51 patients were included in the analysis. The assessment of GIST rupture was based on Nishida’s classification. Twenty patients who were diagnosed before November 2013 were treated with 5 years of imatinib, and 31 patients who were diagnosed after November 2013 were treated with 3 years of imatinib. We retrospectively compared the clinical outcomes of the two groups.Results Baseline characteristics and the incidence of the adverse events were generally comparable between the two groups. During a median follow-up duration of 43.8 months and 104.2 months in the 3- and 5-year group, 8 and 9 patients had a disease recurrence, respectively. The 5-year group showed better recurrence-free survival (RFS) than the 3-year group. In multivariate analysis, low mitotic index was a significant independent favorable prognostic factor for RFS, while 5-year imatinib treatment was marginally associated with a favorable RFS.Conclusion Five years of adjuvant imatinib treatment in patients with ruptured GIST was associated with favorable survival outcomes with manageable toxicity profiles. Our findings warrant validation and confirmation in future studies.
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2021.1040
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2022
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5
    Korean Cancer Association ; 2021
    In:  Cancer Research and Treatment Vol. 53, No. 4 ( 2021-10-15), p. 1166-1173
    Details
    In: Cancer Research and Treatment, Korean Cancer Association, Vol. 53, No. 4 ( 2021-10-15), p. 1166-1173
    Abstract: Purpose This study aimed to investigate the clinical outcomes with gemcitabine-carboplatin (GCb), the standard treatment for patients with advanced urothelial carcinoma (UC) who are ineligible for cisplatin-based regimens, in advanced UC patients with a glomerular filtration rate (GFR) 〈 30 mL/min.Materials and Methods A retrospective cohort study involving GCb-treated advanced UC patients with GFR 〈 60 mL/min (n=89) was performed. Clinical outcomes were compared between subgroups with GFR 〈 30 mL/min and GFR ≥ 30 mL/min but 〈 60 mL/min.Results Most baseline characteristics were comparable between the two subgroups. Patients with GFR 〈 30 mL/min had a significantly lower objective response rate (12.5%) compared to those with higher GFR levels (56.7%) (p=0.004). The number of GCb cycles was significantly lower in patients with GFR 〈 30 mL/min (median 2 cycles) than in those with higher GFR levels (median 6 cycles) (p=0.002). Compared to those with GFR ≥ 30 mL/min but 〈 60 mL/min, patients with GFR 〈 30 mL/min showed significantly worse progression-free survival (PFS) and overall survival (OS) (p 〈 0.001 for both). Further stratification of patient subgroups according to their GFR (i.e., GFR ≥ 45 mL/min but 〈 60 mL/min vs. GFR ≥ 30 mL/min but 〈 45 mL/min vs. GFR 〈 30 mL/min) revealed significantly different PFS and OS (p 〈 0.001 for both).Conclusion The use of GCb is discouraged in advanced UC patients with GFR 〈 30 mL/min. Alternative therapeutic approaches with better efficacy are warranted for these patients.
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2021.091
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2021
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
    Korean Cancer Association ; 2022
    In:  Cancer Research and Treatment Vol. 54, No. 1 ( 2022-01-15), p. 226-233
    Details
    In: Cancer Research and Treatment, Korean Cancer Association, Vol. 54, No. 1 ( 2022-01-15), p. 226-233
    Abstract: Purpose This study aims to evaluate the prognosis of pathologically node-positive bladder cancer after neoadjuvant chemotherapy, the role of adjuvant chemotherapy in these patients, and the value of preoperative clinical evaluation for lymph node metastases.Materials and Methods Patients who received neoadjuvant chemotherapy followed by partial/radical cystectomy and had pathologically confirmed lymph node metastases between January 2007 and December 2019 were identified and analyzed.Results A total of 53 patients were included in the study. The median age was 61 years (range, 34 to 81 years) with males comprising 86.8%. Among the 52 patients with post-neoadjuvant/pre-operative computed tomography results, only 33 patients (63.5%) were considered positive for lymph node metastasis. Sixteen patients (30.2%) received adjuvant chemotherapy (AC group), and 37 patients did not (no AC group). With the median follow-up duration of 67.7 months, the median recurrence-free survival (RFS) and the median overall survival (OS) was 8.5 months and 16.2 months, respectively. The 2-year RFS and OS rates were 23.3% and 34.6%, respectively. RFS and OS did not differ between the AC group and no AC group (median RFS, 8.8 months vs. 6.8 months, p=0.772; median OS, 16.1 months vs. 16.3 months, p=0.479). Thirty-eight patients (71.7%) experienced recurrence. Distant metastases were the dominant pattern of failure in both the AC group (91.7%) and no AC group (76.9%).Conclusion Patients with lymph node-positive disease after neoadjuvant chemotherapy followed by surgery showed high recurrence rates with limited survival outcomes. Little benefit was observed with the addition of adjuvant chemotherapy.
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    URL: Article
    DOI: 10.4143/crt.2021.365
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2022
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...